▎What is Tesamoreli？
Tesamoreli is a synthetic growth hormone-releasing hormone (GHRH) analog. By mimicking the naturally occurring GHRH in the human body, it stimulates the anterior pituitary gland to release growth hormone (GH), thereby increasing the level of serum insulin-like growth factor I (IGF-I). In this way, Tesamoreli can regulate the body's growth hormone axis, affect the secretion and release of growth hormone, and thus have an impact on the body's metabolism, growth and development, as well as various physiological functions. Tesamoreli is mainly used to treat lipid metabolism disorders caused by antiretroviral therapy (ART) in HIV-infected individuals, especially the excessive accumulation of abdominal fat. In addition, it also shows certain potential in improving fat distribution, reducing visceral fat, and enhancing metabolic health.
During the treatment of GH deficiency with rhGH, clinical efficacy coexists with adverse side effects. These adverse side effects have prompted researchers to search for new treatment strategies, thus promoting the development of GFR analogs. GFR analogs are expected to maintain a certain therapeutic effect while reducing adverse side effects and improving patients' tolerability.
As a synthetic GFR, the development of Tesamoreli is mainly aimed at diseases that may be related to a relative deficiency of GH. Among them, HIV-related lipodystrophy is one of its important potential indications. HIV patients often experience symptoms of lipodystrophy, which not only affects the appearance of patients but may also lead to a series of health problems. Therefore, the development of an effective treatment method is crucial for improving the quality of life of HIV patients.
